Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Immunogenicity of Engerix-B and Effect of Booster Injections
NCT00169858Phase 4Completed
- Sponsor
- Université Laval
- Start
- Sep 1995
- Primary completion
- Oct 2011
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (4 arms), sponsored by Université Laval. Primary endpoint: Persistence of antibodies to Engerix-B at age 25. Started Sep 1995; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00169858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169858.